Lenalidomide in the treatment of multiple myeloma

American Journal of Health-System Pharmacy

Volumn 64, Issue 17, 2007, Pages 1799-1807

  Rao, Kamakshi V ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Antineoplastic agents; Combined therapy; Costs; Dexamethasone; Dosage; Drug administration; Lenalidomide; Mechanism of action; Multiple myeloma; Pregnancy; Steroids, cortico ; Teratogenicity

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; GAMMA INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; VASCULOTROPIN; VINCRISTINE SULFATE; WARFARIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMMUNOLOGIC FACTOR;

ANEMIA; ANGIOGENESIS; ANOREXIA; ANXIETY DISORDER; APOPTOSIS; ARTHRALGIA; ASTHENIA; BACKACHE; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; COUGHING; CYTOKINE PRODUCTION; CYTOPENIA; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; INSOMNIA; INTERFERON PRODUCTION; LEG CRAMP; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE WEAKNESS; MYELOMA CELL; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL EDEMA; PHARMACY; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION; ANIMAL; DRUG APPROVAL; ECONOMICS; PATIENT EDUCATION; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DEXAMETHASONE; DRUG APPROVAL; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE MYELOMA; PATIENT EDUCATION; THALIDOMIDE; UNITED STATES;

EID: 34848817128     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070029     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57:43-66.
2. Lenz W, Knapp K. Thalidomide embryopathy. Arch Environ Health. 1962; 5:100-5.
3. Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med. 1962; 267:1184-92,1238-44.
4. Munshi N, Wilson CS, Penn J et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies. Blood. 1998; 92(suppl 1):98a. Abstract.
5. Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87:503-8.
6. Vacca A, Di Loreto M, Ribatti D et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules: LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol. 1995; 50:9-14.
7. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341:1565-71.
8. Barlogie B, Desikan R, Edelmon P et al. Extended survival in advanced and refactory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98:492-4.
9. Grosbois B, Belissant E, Moreau P et al. Thalidomide in the treatment of advanced multiple myeloma: a prospective study of 120 patients. Blood. 2001; 98:689. Abstract.
10. Kumar S, Gertz MA, Dispenzieri A et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003; 78:34-9.
11. Yakoub-Agha I, Moreau P, Leyvraz S et al. Thalidomide in patients with advanced multiple myeloma. Hematol J. 2000; 1:186-9.
12. Hus M, Dmoszynksa A, Soroka-Wojtaszko M et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001; 86:404-8.
13. Blade J, Esteve J, Rosinol L et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol. 2001; 28:588-92.
14. Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica. 2002; 87:408-14.
15. Wu KL, Helgason HH, Van Der Holt B et al. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasma-cytomas. Leukemia. 2005; 19:143-5.
16. Palumbo A, Giaccone L, Bertola A et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001; 86:399-403.
17. Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001; 12:991-5.
18. Palumbo A, Bertola A, Musto P et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. Blood. 2004; 104(11):abstract 207.
19. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003; 21:16-9.
20. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002; 20:4319-23.
21. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24:431-6.
22. Anderson KC. Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Semin Hematol. 2005; 42(4 suppl 4):S3-8.
23. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000; 96:2943-50.
24. Niwayama S, Turk IS, Liu JO. Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem. 1996; 39:3044-5.
25. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004; 4:314-22.
26. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996; 31:213-21.
27. Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001; 15:1950-61.
28. Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002; 100:3063-7.
29. Zangari M, Tricot G, Zeldis J et al. Results of a phase I study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy. Blood. 2001; 96:3226a. Abstract.
30. Richardson PG, Blood E, Mitsiades CS et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006; 108:3458-64.
31. Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20:1467-73.
32. Weber D. IMiDs: results of Phase III studies in relapsed/refractory myeloma. Virtual presentation at the 2005 American Society of Clinical Oncology Annual Meeting. www.asco.org/portal/site/ASCO/menuitem. d3934b88626d03a781d54d10ee37a01d/?vgnextoid= 8a7calf903878010VgnVCM100000f2730ad1RCRD&spk=Weber%2C+Donna+%5Bfau%5D& epdAbst=N&epdVM=Y&epdJCO=N&epdPubMed=N&epdEdBook=N&index=n (accessed 2007 May 2).
33. Baz R, Walker E, Karam MA et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006; 17:1766-71.
34. Richardson PG, Jagannath S, Avigan DE et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma: final results of a multicenter phase 1 trial. Blood. 2006; 108(11):abstract 405.
35. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005; 106:4050-3.
36. Lacy M, Gertz M, Dispenzieri A et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood. 2006; 108(11):abstract 798.
37. Corso A, Lorenzi A, Terulla V et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004; 83:588-91.
38. Kaushal V, Kaushal GP, Melkaveri SN et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost. 2004; 2:327-34.
39. Zangari M, Saghafifar F, Anaissie E et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002; 13:187-92.
40. Zonder JA, Barlogie B, Durie BG et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006; 108:403-4.
41. Rajkumar SV, Jacobus S, Callender N et al. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (e4a03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2006; 108(11):abstract 799.
42. Palumbo A, Rus C, Zeldis JB. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost. 2006; 4:1842-5.
43. Celgene Corporatin. RevAssist for prescribers. www.revlimid.com/hcp/hc= revassist-pre.aspx (accessed 2007 Jun 21).
44. Red Book Update. 2007; 26(Apr):53.